REVIEW

Review
  • 文章类型: Journal Article
    怀孕期间由尿路感染(UTI)引起的肺损伤很少见。在患有UTI的妊娠患者中及时检测肺部并发症对于防止母亲和胎儿的不良结局至关重要。这些并发症可能包括呼吸问题,肺水肿,以及先前存在的疾病的恶化,比如哮喘。我们旨在检测妊娠中UTI术后肺损伤的报告病例。
    我们通过详细的搜索策略,回顾性审查了截至2023年9月PubMed数据库中关于妊娠UTI后肺损伤的报道病例和文章。对选定的15篇文章的标题和摘要进行了评估,最终,根据我们的纳入和排除标准选择了7篇文章。
    大约1-2%的女性可能因持续性尿路感染而发展为急性肾盂肾炎,在某些情况下,这与肺水肿的风险增加有关。尿路感染会影响肺部健康。尿毒症,UTI的结果,会导致呼吸驱动的改变,力学,肌肉功能,和气体交换。此外,尿路感染引起的炎症激活嗜中性粒细胞并促进其募集到肺部,损害肺功能和损害周围组织。
    尽管对该主题的系统研究有限,尿路感染和肺损伤之间可能有联系。然而,目前尚不清楚妊娠是否会加剧这种关联.为了孕产妇健康,儿童健康,以及整个公共卫生,提高医生和妇科医生的认识很重要,以及不同的专业,如急诊和重症监护病房,关于妊娠UTI后肺损伤的更多信息;重要的是要注意UTI可能不会直接导致肺部并发症,但是与怀孕相关的生理变化会增加这种风险,所以更多的关心,观察,早期发现,和治疗对于治疗这些并发症和在患有UTI的孕妇中获得最佳结果至关重要。这方面需要更多的研究,由于妊娠UTI后肺损伤存在的潜在机制尚不清楚。
    UNASSIGNED: Pulmonary injuries resulting from urinary tract infections (UTIs) during pregnancy are rare. Prompt detection of pulmonary complications in pregnant patients with UTIs is crucial to prevent adverse outcomes in both the mother and the fetus. These complications may include respiratory issues, pulmonary edema, and exacerbation of preexisting conditions, such as asthma. We aimed to detect reported cases of pulmonary injury after UTIs among pregnancies.
    UNASSIGNED: We retrospectively reviewed the reported cases and articles in the PubMed database up to September 2023 on pulmonary injury after UTIs among pregnancies through a detailed search strategy. The titles and abstracts of the selected 15 articles were assessed, and ultimately, 7 articles were chosen based on adherence to our inclusion and exclusion criteria.
    UNASSIGNED: Approximately 1-2% of women may develop acute pyelonephritis due to persistent UTIs, which has been associated with an increased risk of pulmonary edema in certain cases. UTIs can affect pulmonary health. Uremia, a consequence of UTIs, can lead to alterations in the respiratory drive, mechanics, muscle function, and gas exchange. Furthermore, urinary infection-induced inflammation activates neutrophils and promotes their recruitment to the lungs, compromising lung function and damaging the surrounding tissue.
    UNASSIGNED: Although systematic research on this topic is limited, there may be a link between UTIs and pulmonary damage. However, it remains unclear whether pregnancy exacerbates this association. For maternal health, child health, and the whole public health, it is important to raise awareness of physicians and gynecologists, as well as the different specialties like emergency and intensive care units, with more information about pulmonary injury after UTI in pregnancy; it is important to note that UTIs may not directly cause pulmonary complications, but physiological changes associated with pregnancy can increase this risk, so more care, observation, early detection, and treatment are critical for treating these complications and achieving best outcome in pregnant women with UTIs. More research is needed in this area, as the mechanism underlying the existence of pulmonary damage post-UTI in pregnancy is unclear.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    本系统评价胃癌根治术后早期经口进食(EOF)的可行性和安全性。一项全面的文献检索确定了8项符合条件的研究,包括临床试验和队列研究,在2011年至2020年之间进行。该综述分析了术后并发症等结果,住院时间,第一次排气/排便时间,和营养标记的变化。研究结果表明,EOF总体上是可行的,耐受性良好,各研究报告的依从率高。大多数患者在术后72小时内成功开始口服摄入,而没有明显的方案偏差。关于安全,研究报告,与传统喂养方案相比,EOF组的术后并发症发生率相当或更低,尽管有些人注意到EOF的并发症没有显着增加。几项研究观察到EOF的潜在好处,包括缩短住院时间,早期恢复胃肠功能,改善营养状况。然而,结果喜忧参半,一些研究发现这些结果没有显着差异。虽然审查表明EOF是胃癌根治术后治疗的可行选择,它强调了患者特定因素和实施过程中密切监测的重要性.研究设计中的异质性,EOF协议,和结果测量限制了直接比较。未来的大规模随机对照试验有必要建立标准化的EOF方案,并为该患者人群提供更有力的证据。
    This systematic review examines the feasibility and safety of early oral feeding (EOF) after radical gastrectomy in patients with gastric cancer. A comprehensive literature search identified eight eligible studies, including both clinical trials and cohort studies, conducted between 2011 and 2020. The review analyzed outcomes such as postoperative complications, length of hospital stay, time to first flatus/bowel movement, and changes in nutritional markers. The findings suggest that EOF is generally feasible and well-tolerated, with high adherence rates reported across studies. Most patients successfully initiated oral intake within 72 hours post-surgery without significant protocol deviations. Regarding safety, the studies reported comparable or lower rates of postoperative complications in EOF groups compared to traditional feeding protocols, though some noted non-significant increases in complications with EOF. Several studies observed potential benefits of EOF, including shorter hospital stays, earlier return of gastrointestinal function, and improved nutritional status. However, the results were mixed, with some studies finding no significant differences in these outcomes. While the review suggests EOF is a viable option for postoperative management after radical gastrectomy, it emphasizes the importance of patient-specific factors and close monitoring during implementation. The heterogeneity in study designs, EOF protocols, and outcome measures limits direct comparisons. Future large-scale randomized controlled trials are warranted to establish standardized EOF protocols and provide more robust evidence for this patient population.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    准备科学手稿的过程错综复杂,包括几个关键阶段,包括写作前,研究开发,起草,同行评审,编辑,出版物,传播,和访问。其中,同行评审流程(PRP)是需要编辑之间无缝协作的关键组成部分,审稿人,和作者。审稿人在评估手稿质量和提供建设性反馈方面发挥着至关重要的作用,哪些作者必须熟练地导航以增强他们的工作并满足期刊标准。这个过程往往会显得令人生畏和耗时,因为作者需要解决许多评论和要求的更改。鼓励作者将审稿人视为顾问而不是对手,将他们的批评视为改进的机会,而不是人身攻击。
    意见文章。
    为作者提供有效参与PRP并提高其出版接受率的实用策略。
    关键准则包括彻底理解和优先反馈,保持专业性,并系统地解决每个评论。在重大分歧或误解的情况下,作者可以选择将问题提交给编辑。制作组织良好且科学的“对评论的回应”以及修订后的手稿可以大大增加接受的可能性。撰写有效回应评论的最佳做法包括表达感激之情,首先解决重大修改,征求合著者和同事的意见,并严格遵守期刊指南。强调规划对策的重要性,强调修订后的手稿的变化,并进行最终审查,确保所有更正都得到适当记录。
    遵循这些准则,作者可以提高他们的手稿质量,培养与审稿人的积极关系,并最终促进学术进步。
    UNASSIGNED: The process of preparing a scientific manuscript is intricate, encompassing several critical stages, including pre-writing, research development, drafting, peer review, editing, publication, dissemination, and access. Among these, the peer review process (PRP) stands out as a pivotal component requiring seamless collaboration among editors, reviewers, and authors. Reviewers play a crucial role in assessing the manuscript\'s quality and providing constructive feedback, which authors must adeptly navigate to enhance their work and meet journal standards. This process can often appear daunting and time-consuming, as authors are required to address numerous comments and requested changes. Authors are encouraged to perceive reviewers as consultants rather than adversaries, viewing their critiques as opportunities for improvement rather than personal attacks.
    UNASSIGNED: Opinion article.
    UNASSIGNED: To equip authors with practical strategies for engaging effectively in the PRP and improving their publication acceptance rates.
    UNASSIGNED: Key guidelines include thoroughly understanding and prioritizing feedback, maintaining professionalism, and systematically addressing each comment. In cases of significant disagreement or misunderstanding, authors have the option to refer the issue to the editor. Crafting a well-organized and scientific \"response to reviews\" along with the revised manuscript can substantially increase the likelihood of acceptance. Best practices for writing an effective response to reviews include expressing gratitude, addressing major revisions first, seeking opinions from co-authors and colleagues, and adhering strictly to journal guidelines. Emphasizing the importance of planning responses, highlighting changes in the revised manuscript, and conducting a final review ensures all corrections are properly documented.
    UNASSIGNED: By following these guidelines, authors can enhance their manuscripts\' quality, foster positive relationships with reviewers, and ultimately contribute to scholarly advancement.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    全球约80%的肾癌是透明细胞肾癌(ccRCC)。这些恶性肿瘤中有80%具有VonHippel-Lindau基因的失活突变。这种遗传改变导致缺氧诱导因子1和2α(HIF1和2α)的稳定,导致靶基因如血管内皮生长因子(VEGF)的过表达,这对血管生成至关重要。因此,ccRCC是高度血管化的,并且用作抗血管生成治疗(AAT)的模型。目前的AAT疗法包括靶向VEGF的抗体,靶向新血管生成受体的酪氨酸激酶抑制剂(TKi)(舒尼替尼),和捕获VEGFA和PlGF的竞争性抑制剂受体(阿柏西普)。VEGF和相关成员如VEGFC的过表达显著影响血管生成,淋巴管生成,和免疫耐受。这导致各种免疫检查点抑制剂(称为抗PD-1、抗PD-L1和抗CTLA-4)被批准为肾癌的可行治疗选择。尽管取得了这些进展,ccRCC仍然难以充分治疗。因此,为了更好地了解RCC的生物学和病理生理学,未来的研究势在必行。肿瘤微环境,和抵抗机制,目的是开发新的疗法。
    Approximatively 80% of kidney cancers globally are clear cell kidney cancers (ccRCCs), with 80% of these malignancies featuring an inactivating mutation of the Von Hippel-Lindau gene. This genetic alteration leads to the stabilization of hypoxia inducible factors 1 and 2 alpha (HIF 1 and 2α), resulting in the over-expression of target genes such as vascular endothelial growth factor (VEGF), which is crucial for angiogenesis. As a result, ccRCCs are highly vascularized and serve as models for anti-angiogenic treatments (AAT). Current AAT therapies comprise antibodies targeting VEGFs, tyrosine kinase inhibitors (TKi) (Sunitinib) that target neo-angiogenesis receptors, and competitive inhibitor receptors (Aflibercept) that trap VEGFA and PlGF. The over-expression of VEGF and related members such as VEGFC significantly influences angiogenesis, lymph-angiogenesis, and immune tolerance. This has resulted in the approval of various immune checkpoint inhibitors (known as anti-PD-1, anti-PD-L1, and anti-CTLA-4) as viable treatment options for kidney cancer. Despite these advances, ccRCC remains challenging to treat adequately. Thus, future research is imperative to better understand the biology and pathophysiology of RCC, the tumor microenvironment, and mechanisms of resistance, with the aim of developing new therapies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    实验显微外科领域是由伟大的显微外科医生孙李开创的,他在诊所建立了移植手术的基础。Lee博士在引入显微外科手术以建立癌症小鼠模型方面也发挥了开创性作用。1990年,年仅70岁的Lee博士向AntiCancerInc.的小鼠模型团队展示了显微外科技术。导致了外科原位植入(SOI)技术的发展以及第一个以类似于临床癌症的方式转移的癌症原位小鼠模型。在本世纪初,来自金泽大学医学院的一位(NY)成为AntiCancer的客座科学家,学习SOI并使用表达荧光报告基因的癌细胞开发癌症的小鼠模型,如绿色荧光蛋白(GFP)和红色荧光蛋白(RFP),以便实时成像转移性癌细胞运输。从那以后,来自金泽大学的八位年轻外科医生一直在参观AntiCancer的研究人员,开发SOI小鼠癌症模型以在体内可视化癌细胞,实时跟踪转移的所有阶段。本透视综述总结了这项开创性的工作,这彻底改变了转移研究领域。
    The field of experimental microsurgery was pioneered by the great microsurgeon Sun Lee, who developed the foundation of transplant surgery in the clinic. Dr Lee also played a seminal role in introducing microsurgery to establish mouse models of cancer. In 1990, at the age of 70, Dr Lee demonstrated microsurgery techniques to the mouse-model team at AntiCancer Inc., leading to the development of the surgical orthotopic implant (SOI) technique and the first orthotopic mouse models of cancer that metastasized in a pattern similar to clinical cancer. At the beginning of the present century, one of us (NY) from Kanazawa University School of Medicine became a visiting scientist at AntiCancer to learn SOI and develop mouse models of cancer using cancer cells expressing fluorescent reporter genes, such as green fluorescent protein (GFP) and red fluorescent protein (RFP), in order to image metastatic cancer cells trafficking in real time. Since then, a total of eight young surgeons from Kanazawa University have been visiting researchers at AntiCancer, developing SOI mouse models of cancer to visualize cancer cells in vivo, tracking all stages of metastasis in real time. The present perspective review summarizes this seminal work, which has revolutionized the field of metastasis research.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    心脏是一个多细胞系统,细胞间串扰机制对心脏甚至器官的生长发育非常重要,组织,和远处的细胞。作为一种细胞外囊泡,外泌体由不同类型的细胞释放,可以携带特定的遗传物质,内体蛋白,细胞因子,等。,这是调解细胞串扰机制的主要物质基础。其中,由心脏细胞来源的外泌体携带的microRNA具有高度保守的序列,在调节器官功能中起关键作用,组织,以及与心血管疾病及其并发症和合并症有关的细胞,近年来引起了医学界的广泛关注。跟踪国内外最新研究进展,本文系统综述了心脏细胞来源的外泌体microRNA在各种细胞串扰中的调节作用,不仅包括心肌细胞(包括心肌细胞,成纤维细胞,成肌纤维细胞,心脏祖细胞,心脏微血管内皮细胞,心球来源的细胞,等。)但也有肿瘤细胞,骨髓祖细胞,和其他组织细胞,为心血管疾病及其并发症和合并症的防治提供参考。
    The heart is a multicellular system, and the intercellular crosstalk mechanism is very important for the growth and development of the heart and even the organs, tissues, and cells at a distance. As a kind of extracellular vesicle, exosomes are released by different types of cells and can carry specific genetic material, endosomal proteins, cytokines, etc., which are the main material basis for mediating cell crosstalk mechanism. Among them, microRNA carried by cardiac cells-derived exosomes have highly conserved sequences and play a key role in regulating the function of organs, tissues, and cells related to cardiovascular diseases and their complications and comorbidities, which have attracted extensive attention in the medical community in recent years. Following up on the latest research progress at home and abroad, this review systematically summarized the regulatory role of microRNA from cardiac cells-derived exosomes in various cell crosstalk, including not only cardiac cells (including cardiomyocytes, fibroblasts, myofibroblast, cardiac progenitor cells, cardiac microvascular endothelial cells, cardiosphere-derived cells, etc.) but also tumor cells, bone marrow progenitor cells, and other tissue cells, in order to provide a reference for the prevention and treatment of cardiovascular diseases and their complications and comorbidities.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    具有冷酷无情(CU)特征的青少年面临着生活质量差的风险,例如监禁,自杀,和精神病。目前尚不清楚哪些治疗是专门针对CU青少年实施的,哪些因素构成了这些干预措施。使用叙述性系统评价来确定CU青少年(12-18岁)的治疗方法和常用元素。符合条件的研究是评估心理社会干预的随机对照试验和准实验研究。在临床背景下交付,并指向青少年或他们的家人。包括1291名参与者的8项研究。仅在少数研究中证明了CU性状的显着降低。利用最多的实践要素是设定治疗目标,练习人际交往/沟通技巧,准备终止,并教父母技能和策略;最常用的过程元素是正式治疗,练习练习,重要的其他人,和灵活/自适应。大多数研究没有报告实施要素。虽然CU儿童的理论框架适用于CU青少年,他们是否适合这个年龄组仍不确定.鉴于经验证据有限,迫切需要进一步探索。
    Adolescents with callous unemotional (CU) traits are at risk for poor quality-of-life outcomes such as incarceration, suicide, and psychopathy. It is currently unknown which treatments are implemented with CU adolescents specifically and which elements make up these interventions. A narrative systematic review was used to identify the treatments and common elements used with CU adolescents (12-18 years). Eligible studies were randomized controlled trials and quasi-experimental studies evaluating psychosocial interventions, delivered within a clinical context, and directed towards the adolescent or their family. Eight studies with 1291 participants were included. Significant decreases in CU traits were demonstrated only in a minority of studies. The most utilized practice elements were set goals for treatment, practice interpersonal/communication skills, prepare for termination, and teach parents skills and strategies; the most utilized process elements were formal therapy, practice exercises, important others, and flexible/adaptive. A majority of the studies did not report an implementation element. While theoretical frameworks for CU children are employed with CU adolescents, there is still uncertainty regarding their suitability for this age group. Given the limited empirical evidence, there is a critical need for further exploration.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:越来越多的证据表明,lncRNAABHD11-AS1在肿瘤发生中起着至关重要的作用,并有望成为新的预测生物标志物和癌症治疗的理想靶点。而他们的一些发现由于个别研究的样本量相对较小而相互矛盾。因此,本荟萃分析旨在定量确定ABHD11-AS1与多种人类恶性肿瘤的相关性.
    方法:2024年1月1日对8个数据库进行了相关文章的综合筛选。ABHD11-AS1在恶性肿瘤中的意义通过比值比(ORs)或风险比(HRs)和相应的95%置信区间(CI)确定。应用亚组分析和敏感性分析来验证合并结果的可靠性和稳健性。同时,GEPIA2021和UCSCXena数据库被应用于进一步加强结果。
    结果:本荟萃分析纳入了14项临床研究,包括8种恶性肿瘤和1215例恶性肿瘤病例。合并结果显示ABHD11-AS1表达增加与淋巴结转移显著相关(OR=2.73,95CI[1.97,3.77],I2=0%,p<0.00001),晚期肿瘤分期(OR=3.14,95CI[2.34,4.21],I2=39%,p<0.00001),和不利的总生存期(OS)(HR=1.81,95CI[1.58,2.06],I2=0%,p<0.00001)。亚组分析和敏感性分析表明,合并结果可靠且稳健。此外,根据GEPIA2021数据库的验证,ABHD11-AS1在8种恶性肿瘤中显著升高。同时,UCSCXena数据库进一步显示ABHD11-AS1表达升高与无进展间期(PFI)评估的不良预后显著相关,无病间隔(DFI),疾病特异性生存率(DSS),和OS。
    结论:目前的证据支持ABHD11-AS1表达升高与不良预后相关。因此,ABHD11-AS1可能被认为是筛查癌症和预测恶性肿瘤预后的有前途的生物标志物。此外,有必要采用不同国家的统一研究方案进行更大规模的多中心研究,以进一步验证结论.
    BACKGROUND: Accumulating evidence has highlighted that lncRNA ABHD11-AS1 plays an essential role in tumorigenesis and is expected to become a new predictive biomarker and ideal target for cancer therapy, whereas some of their findings are conflicting due to the relatively small sample size of individual studies. Thus, this meta-analysis aimed to quantitatively ascertain the association of ABHD11-AS1 with diverse human malignancies.
    METHODS: Eight databases were comprehensively screened for relevant articles on January 1, 2024. The significance of ABHD11-AS1 in malignancies was determined by odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% confidence interval (CI). Subgroup analyses and sensitivity analyses were applied to verify the reliability and robustness of the pooled results. Simultaneously, the GEPIA2021 and UCSC Xena databases were applied to further strengthen the results.
    RESULTS: Fourteen clinical studies comprising eight kinds of malignancies and 1215 malignancy cases were enrolled into this meta-analysis. The pooled results showed that increased ABHD11-AS1 expression was remarkably associated with lymph node metastasis (OR = 2.73, 95%CI [1.97, 3.77], I2 = 0%, p < 0.00001), advanced tumor stage ( OR = 3.14, 95%CI [2.34, 4.21], I2 = 39%, p < 0.00001), and unfavorable overall survival (OS) (HR = 1.81, 95%CI [1.58, 2.06], I2 = 0%, p < 0.00001). Subgroup analyses and sensitivity analyses indicated that the pooled results were reliable and robust. Additionally, ABHD11-AS1 was significantly increased in eight kinds of malignancies according to the validation of the GEPIA2021 database. Meanwhile, the UCSC Xena databases further revealed that elevated ABHD11-AS1 expression was significantly associated with poor prognosis as assessed by progression free interval (PFI), disease free interval (DFI), disease specific survival (DSS), and OS.
    CONCLUSIONS: Current evidence supports the association of elevated ABHD11-AS1 expression with poor prognosis. Thereby, ABHD11-AS1 may be considered as a promising biomarker to screen cancer and predict malignancy prognosis. Also, there is a necessity for larger-scale multicenter studies with uniform study protocols from different countries to further validate the conclusions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    振动控制对于无数的机械系统来说是极其重要的。Inerter是2002年提出的一种双端动态元件,基于机械系统和电气系统之间的类比。理想惰器的动态特性是纯惯性。施加在惰性器的每个端子上的力与两个端子的相对加速度成正比。自从惰性剂提出以来,它在振动控制系统方面取得了重大进展。本文是关于惰器的物理实现以及基于惰器的振动控制的综述。物理实现和在惯性器振动控制中的应用是重点。首先,介绍了惰性剂的发展和惰性剂的典型物理实现。总结了基于拉格朗日方程方法的不同惯性中动态关系的规范推导过程。然后,介绍了常见的基于惰器的振动控制系统的三类。最后,总结了惰性剂物理实现的研究趋势,并讨论了基于惰器的振动控制的可能研究。
    Vibration control is extremely important for countless mechanical systems. Inerter is a two-terminal dynamic element proposed in 2002, based on analogy between mechanical system and electric system. Dynamic characteristic of an ideal inerter is pure inertia. Force applied on each terminal of an inerter is directly proportional to relative acceleration of two terminals. Since inerter was put forward, it has made significant progress in vibration control systems. The paper is a review about physical realizations of inerter as well as inerter-based vibration control. Physical realizations and applications in vibration control of inerter are focused. First, the develop of inerter and typical physical realizations of inerter are introduced. The normative derivation processes based on Lagrange equation method of the dynamic relationships in the different inerters are summarized. And then, three categories of common inerter-based vibration control systems are explained. Finally, research trend of physical realizations of inerter are summarized, and the possible researches on inerter-based vibration control are discussed.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    尽管癌症研究取得了进展,上皮性卵巢癌仍然是女性健康的主要威胁,五年生存率低,为48%。晚期病例的预后,特别是国际妇产科联合会(FIGO)III-IV,很穷。标准护理包括手术切除和铂类化疗,但70-80%面临复发和化疗耐药。近年来,三维(3D)癌症模型,尤其是患者来源的类器官(PDO),彻底改变了癌症研究的个性化治疗。通过超越传统模型的约束,类器官准确地概括了关键的形态学,组织学,和疾病的遗传特征,特别是在卵巢癌的背景下。探索了卵巢癌类器官的广泛潜力,从基础理论到尖端应用。作为有效的临床前模型,类器官为预测患者治疗反应和指导个性化治疗策略的开发提供了宝贵的工具。此外,在药物评估领域,类器官展示了它们作为平台的独特多功能性,能够对创新药物组合和新型候选药物进行全面测试,从而开拓了药物研究的新途径。值得注意的是,类器官模拟卵巢癌的动态进展,从开始到系统传播,揭示复杂而微妙的疾病机制,并提供关键的见解。在个性化水平上运作,类器官还揭示了耐药背后的复杂机制,为制定有效的治疗策略提供战略机遇。这篇综述总结了卵巢癌类器官的新兴作用,在三维模型中精心培育的细胞簇,作为一个开创性的研究范式。
    Despite advancements in cancer research, epithelial ovarian cancer remains a leading threat to women\'s health with a low five-year survival rate of 48%. Prognosis for advanced cases, especially International Federation of Gynecology and Obstetrics (FIGO) III-IV, is poor. Standard care includes surgical resection and platinum-based chemo, but 70-80% face recurrence and chemoresistance. In recent years, three- dimensional (3D) cancer models, especially patients-derived organoids (PDOs), have revolutionized cancer research for personalized treatment. By transcending the constraints of conventional models, organoids accurately recapitulate crucial morphological, histological, and genetic characteristics of diseases, particularly in the context of ovarian cancer. The extensive potential of ovarian cancer organoids is explored, spanning from foundational theories to cutting-edge applications. As potent preclinical models, organoids offer invaluable tools for predicting patient treatment responses and guiding the development of personalized therapeutic strategies. Furthermore, in the arena of drug evaluation, organoids demonstrate their unique versatility as platforms, enabling comprehensive testing of innovative drug combinations and novel candidates, thereby pioneering new avenues in pharmaceutical research. Notably, organoids mimic the dynamic progression of ovarian cancer, from inception to systemic dissemination, shedding light on intricate and subtle disease mechanisms, and providing crucial insights. Operating at an individualized level, organoids also unravel the complex mechanisms underlying drug resistance, presenting strategic opportunities for the development of effective treatment strategies. This review summarizes the emerging role of ovarian cancer organoids, meticulously cultivated cellular clusters within three-dimensional models, as a groundbreaking paradigm in research.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号